Associated Papers
Integrated morphological, immunohistochemical, and genomic profiling identifies uterine leiomyoma patients with hereditary leiomyomatosis and renal cell cancer syndrome: a comprehensive analysis of 252 cases.
Liu Y et al.
The Journal of Pathology, 2026
Fumarate inhibits PTEN to promote tumorigenesis and therapeutic resistance of type2 papillary renal cell carcinoma.
Ge X et al.
Molecular Cell, 2022
A novel pathogenic variant of the FH gene in a family with hereditary leiomyomatosis and renal cell carcinoma.
Yagi Y et al.
Human Genome Variation, 2022
35034951 (PubMed )
Supplement: 41439_2021_180_MOESM1_ESM.pdf
Targeted sequencing of FH-deficient uterine leiomyomas reveals biallelic inactivating somatic fumarase variants and allows characterization of missense variants.
Popp B et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc, 2020
32612247 (PubMed )
Supplement: 41379_2020_596_MOESM2_ESM.xlsx › FH_ClinVar
Novel missense mutation in the FH gene in familial renal cell cancer patients lacking cutaneous leiomyomas.
Kuwada M et al.
Bmc Research Notes, 2014
No evidence for the role of somatic mutations and promoter hypermethylation of FH gene in the tumorigenesis of nonsyndromic uterine leiomyomas.
Vaidya S et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine, 2012
Exploring a glycolytic inhibitor for the treatment of an FH-deficient type-2 papillary RCC.
Yamasaki T et al.
Nature Reviews. Urology, 2011
Select a paper to view details